目錄:MedChemExpress LLC>>生化試劑>> ReACp53 | MCE
參考價(jià) | ¥ 3000 |
參考價(jià) | ¥ 3000 |
更新時(shí)間:2023-06-19 09:18:34瀏覽次數(shù):143評(píng)價(jià)
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息,謝謝!
純度 | 99.87% | 分子量 | 2617.13 |
---|---|---|---|
分子式 | C???H???N??O?? | 供貨周期 | 現(xiàn)貨 |
規(guī)格 | 5 mg | 貨號(hào) | HY-P0121 |
應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥/生物制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
CAS No. :
產(chǎn)品活性:ReACp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.
研究領(lǐng)域:Apoptosis
作用靶點(diǎn):MDM-2/p53
In Vitro: ReACp53 penetrates into HGSOC primary cancer cells and converts mutant p53 from a punctate state into soluble WT-like p53. ReACp53 also induces cancer cell death, cell cycle arrest and results in p53 degradation. ReACp53 specifically affects cell viability and proliferation of cancer cells bearing mutant p53 but not wild type when grown as organoids.
In Vivo: Only mutant p53-bearing tumors in the ReACp53-treated mice cohorts are 80-90% smaller in weight than the control cohort, confirming the ability of ReACp53 to limit tumor proliferation and shrink tumors. A significant reduction of Ki67 positive cells is evident in ReACp53-treated OVCAR3 xenografts, indicative of a reduced proliferative index. Similar results are observed in the minimal residual disease model. In the paradigm, administration of ReACp53 results in a significant increase in p21 and MDM2 transcription in OVCAR3 but not MCF7 xenografts. A significantly increased population is also found in G0/G1 phase, supporting proliferative arrest upon ReACp53 administration in vivo.
相關(guān)產(chǎn)品:Bioactive Compound Library Plus | Peptide Library | p53 (17-26) | p53 and MDM2 proteins-interaction-inhibitor (racemic) | Navtemadlin | Antitumor agent-60 | Roslin 2 bromide | Amifostine trihydrate | MX69 | ADH-6 TFA | RG7112 | SCH529074 | CBL0137 hydrochloride | MA242 | MD-224 | MB710 | NSC59984 | MDM2/4-p53-IN-1 | Oxychlororaphine | Pifithrin-β hydrobromide | p53-MDM2-IN-1 | PK11000 | Tenovin-6 | NSC 146109 hydrochloride | Ivaltinostat | FOXO4-DRI acetate | 3-Morpholinosydnonimine | PROTAC MDM2 Degrader-1 | Lobetyol | NSC405640 | CP-31398 dihydrochloride | p53-HDM2-IN-1
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物 | 寡核苷酸 | 抗體 | 點(diǎn)擊化學(xué)
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號(hào)通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測(cè)分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國(guó)客戶實(shí)驗(yàn)驗(yàn)證;
• Nature, Cell, Science 等多種頂級(jí)期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊(duì)跟蹤新的制藥及生命科學(xué)研究進(jìn)展,為您提供*新的活性化合物;
• 與世界各大制藥公司及*科研機(jī)構(gòu)建立了長(zhǎng)期的合作。
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)